Intercept to Report 2016 Full Year Financial Results on February 23 and Present at Upcoming Conferences

NEW YORK, Feb. 17, 2017 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its fourth quarter and full year 2016 financial results prior to the NASDAQ market open on Thursday, February 23, 2017. Intercept management will conduct a conference call and audio webcast on Thursday, February 23, 2017 at 8:30 a.m. Eastern Time to discuss these results.

Intercept management will also be presenting at the following investor conferences:

• 2017 RBC Capital Markets Global Healthcare Conference on February 23, 2017 at 11:30 a.m. Eastern Time
• 37^th Annual Cowen Health Care Conference on March 6, 2017 at 4:40 p.m. Eastern Time

Webcast information for these events will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.

About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.

CONTACT: For more information about

Intercept Pharmaceuticals, please contact:
       

Intercept Pharmaceuticals:

Mark Vignola

+1-646-747-1000

[email protected]

     
Media inquiries: [email protected]
     
Investor inquiries: [email protected]